Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

EMERYVILLE, Calif.: EMERYVILLE, Calif., Jan. 3, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today announced that the company has entered into exclusive, worldwide licenses with the National Institutes of Health (NIH) for intellectual property related to...

Click to view original post